Adc Therapeutics Sa (ADCT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ADCT Annual Cash Flow →
Examining cash flow movements between Adc Therapeutics Sa and Jun 30 2025 reveals how Jun 30 2026 allocates cash as operating conditions evolve.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
6 Months
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-49.53
Depreciation & amortization0.00
Amortization of Other Assets15.37
Special charges0.00
Accountig change2.67
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase4.92
Effect of exchange rate0.00
Sale of Business0.00
Share-based Compensation0.18
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-16.38
Adjustments For Sharebased Payments-
Adjustments For Depreciation Expense Property Plant And Equipment-
Adjustments For Depreciation Expense Of Right Of Use Assets-
Adjustments For Amortisation Expense And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss Intangible Assets-
Share Of Profit Loss Of Joint Ventures Accounted For Using Equity Method-
Adjustments For Increase Decrease In Non Current Net Defined Benefit Liability-
Adjustments For Finance Income-
Adjustments For Finance Costs-
Adjustments For Income Tax Expense-
Cash Flows From Used In Operations Before Changes In Working Capital-
Adjustments For Decrease Increase In Other Current Assets-
Adjustments For Increase Decrease In Contract Liabilities-
Adjustments For Increase Decrease In Trade And Other Payables-
Adjustments For Increase Decrease In Other Liabilities-
Deferred Royalty Obligation Cumulative Catch Up Adjustment-
Pension Expense Reversal Of Expense Noncash-
Operating Lease Right Of Use Asset Amortization Expense0.11
Increase Decrease In Operating Lease Liability-0.25
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-1.08
Increase (Decrease) in Accounts Payable, Trade3.60
Increase (Decrease) in Accrued Liabilities0.64
Payments for (Proceeds from) Other Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.26
Other Working Capital3.40
Other Noncash Income (Expense)0.32
Other net0.00
Payments for (Proceeds from) Other Operating Activities-3.35
Discontinued operations0.00
Net Cash flow from Operating Activities-41.52
Investing Activities
Capital Expenditures-0.03
Sale of Capital Items0.00
Short-term investments liq.0.00
Short-term investments acq.0.00
Proceeds from other investments0.00
Purchases of other investments0.00
Noncontrolling interest0.00
Proceeds from Investments0.00
Purchases of Investments0.00
Purchases of non-current assets0.00
Acquisition net of cash acquired0.00
Investment in affiliate0.00
Sale of businesses0.00
Proceeds from sale of assets0.00
Notes receivable0.00
Other0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.03
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Noncontrolling interest0.00
Issuances / -repurchases of Comm. Stock0.30
Exercise of stock options0.00
Issuances / -repurchases of Pref. Stock0.00
Discontinued Operations0.00
Other financing activities net-0.99
Other net0.00
Proceeds From Royalties Received Net Of Transaction Costs-
Dividends paid to minority interests0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.68
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-41.55
Total Cash Flow-42.23
4 historic quarters locked

Sign in to unlock the full Adc Therapeutics Sa cash flow history.

About Adc Therapeutics Sa Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 13, 2026
  • Source: adc-20260630.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-056711

Figures are derived from filed reports and may be restated. Historical data is subject to revision.